The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.
 
Maria Vittoria Dieci
Consulting or Advisory Role - Exact Sciences; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Seagen
Patents, Royalties, Other Intellectual Property - Patent pending HER2DX licensed to University of Padova
 
Giancarlo Bisagni
No Relationships to Disclose
 
Alba Ariela Brandes
No Relationships to Disclose
 
Antonio Frassoldati
Consulting or Advisory Role - Daiichi Sankyo; Lilly; Novartis Italy; Pfizer; Roche Italy; Seagen
 
Roberto Vicini
No Relationships to Disclose
 
Sara Balduzzi
No Relationships to Disclose
 
Roberto D'Amico
No Relationships to Disclose
 
Pier Franco Conte
Consulting or Advisory Role - Daiichi Sankyo/Lilly; Gilead Sciences; Reveal Genomics
Speakers' Bureau - AstraZeneca; BMS; Lilly; Novartis; Roche/Genentech; Tesaro
Research Funding - BMS (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2Dx patent
Expert Testimony - AstraZeneca; Roche
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis; Pfizer
 
Valentina Guarneri
Consulting or Advisory Role - Gilead Sciences (I); Lilly; MSD; Novartis; Roche
Speakers' Bureau - Lilly; Novartis
Research Funding - GlaxoSmithKline
Travel, Accommodations, Expenses - Celgene; Tesaro